FDA Approves Unspecified — ORIG Submission by HANDA ONCOLOGY, LLC, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows HANDA ONCOLOGY, LLC as the sponsor of Unspecified, with the generic name recorded as unspecified and dosage form unspecified dosage form. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220613, with a submission status date of 20260903. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

HANDA ONCOLOGY, LLC’s FDA history

Argus HQ has recorded 1 total FDA action tied to HANDA ONCOLOGY, LLC: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What review priority did FDA assign?

FDA designated this submission as: STANDARD.

What dosage form is Unspecified?

Unspecified is formulated as: unspecified dosage form.

What did FDA approve?

FDA's record shows nda approval for Unspecified (unspecified), dosage form unspecified dosage form, sponsored by HANDA ONCOLOGY, LLC, under application number NDA220613. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Related enforcement actions

• Approval (recent): LUPIN — ANDA approval: MODAFINIL (unspecified) →
• Approval (recent): ASTRAZENECA PHARMACEUTICALS, LP — NDA approval: ETCAMAH (unspecified) →
• Approval (recent): BPI LABS — ANDA approval: TESTOSTERONE CYPIONATE (unspecified) →
• Approval (recent): ZHEJIANG JUTAI PHARM — ANDA approval: BRIVARACETAM (unspecified) →
• Approval (recent): MSN — ANDA approval: TAPENTADOL HYDROCHLORIDE (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: SACUBITRIL AND VALSARTAN (unspecified) →
• Approval (recent): IONIS PHARMS INC — NDA approval: ZANVASTRO (unspecified) →
• Approval (recent): PRECISION DOSE INC — ANDA approval: ALENDRONATE SODIUM (unspecified) →